This UN decision, which acknowledges medicinal usefulness of cannabis and clarifies that CBD is not under international drug control, is expected to have a substantial impact on Elixinol’s ability to drive product sales in Europe and other countries influenced by UN decision-making.
() (OTCMKTS:ELLXF) (FRA:E8M) is encouraged by a United Nations decision to remove cannabis and its derivatives from schedule IV of the 1961 Single Convention on Narcotic Drugs following recommendations from the World Health Organisation (WHO).
This emanated from WHO recommendation 5.1, which recognises the medical value of cannabis and will see it removed from Schedule IV of the 1961 Convention – reserved for substances with ‘particularly dangerous properties’ and little or no therapeutic value.
UN adoption of the WHO recommendations acknowledges the medicinal usefulness of cannabis and clarifies that cannabidiol (CBD) is not under international control.
This vote followed an independent scientific assessment undertaken by leading experts, convened by WHO in 2017-2018, where evidence and testimonials from all corners of the world were reviewed.
It also follows last week’s landmark ruling from the European Union’s highest court, the Court of Justice of the European Union (CJEU) that CBD is not a narcotic as it does not appear to have any psychotropic…